GLP-1 dose schedules.
What the prescribing documents say about stepping up each medication, and where a given week of treatment falls in them.
These schedules are general information, not medical advice, and no schedule on this page is a prescription for anyone reading it. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Each schedule below is transcribed from the labelling of an approved product and describes that product. A prescribing clinician decides the actual schedule for a patient, and may keep a patient at one step longer, return to a lower step, or stop increasing altogether.
Published schedule — Oral semaglutide (tablet)
- 3 mgWeeks 1–4once daily for 30 days
- 7 mgWeeks 5–8once daily for at least 30 days
- 14 mgWeeks 9–28once daily
The document states this schedule in days rather than weeks — 30 days at the first dose, then at least 30 days at the second — so the week ranges shown are a rounding of it and are not exact. The document also describes the last step as optional, taken only if more blood-sugar control is needed — which is the effect that document measures, and not weight.
Where these schedules come from
Oral semaglutide (tablet)
These weeks are read from the label of an approved oral semaglutide tablet whose escalation is written for blood-sugar control in type 2 diabetes rather than for weight. A separate approved oral semaglutide product for weight reduction exists and publishes different numbers. The tablet prescribed through this site is a compounded preparation in a different form, and it has not been evaluated by the FDA. Nothing here describes what a prescription from this site arrives as or how a prescriber directs it to be taken.
RYBELSUS (semaglutide) tablets, for oral use — Prescribing Information — DailyMed, U.S. National Library of Medicine, revised 2026-08-19
Semaglutide (injection)
These weeks are read from the label of an approved semaglutide injection. What is prescribed through this site is a compounded medication. It is not the product this document describes, and it is not FDA-approved. The schedule a prescriber sets is theirs to set and need not follow this one.
WEGOVY (semaglutide) injection, for subcutaneous use — Prescribing Information — DailyMed, U.S. National Library of Medicine, revised 2026-06-30
Tirzepatide (injection)
These weeks are read from the label of an approved tirzepatide injection. What is prescribed through this site is a compounded medication. It is not the product this document describes, and it is not FDA-approved. The schedule a prescriber sets is theirs to set and need not follow this one.
ZEPBOUND (tirzepatide) injection, for subcutaneous use — Prescribing Information — DailyMed, U.S. National Library of Medicine, revised 2026-09-02
Ready to get started?
Answer a short health questionnaire. A licensed provider reviews it and decides whether a prescription is appropriate for you.